

## Supporting Information

**Addressing Regio- and Stereo-Specificity Challenges in the Synthesis of Nucleoside 2',3'-Cyclic  
Monophosphate Analogs – a Rapid and Facile Synthesis of Nucleosides-2',3'-*O,O*-phosphoro-thioate or -  
selenoate, and Elucidation of the Origin of the Rare Specificity**

Molhm Nassir<sup>a</sup>, Lara Balaom<sup>b</sup>, and Bilha Fischer<sup>a\*</sup>

<sup>a</sup> Department of Chemistry, Bar-Ilan University, Ramat-Gan 52900 Israel

<sup>b</sup>Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn,  
Germany.

\*Address correspondence to:

Bilha Fischer, Department of Chemistry, Bar-Ilan University, Ramat-Gan 52900, Israel

Fax: 972-3-6353907; Tel.: 972-3-5318303; e-mail: [bilha.fischer@biu.ac.il](mailto:bilha.fischer@biu.ac.il)

All authors have approved the final article

## TABLE OF CONTENTS

Experimental .....	3-5
<sup>31</sup> P/ <sup>1</sup> H/ <sup>13</sup> C and DEPT NMR spectra of 2-cyanoethoxy-dithiophospholane, <b>8</b> .....	6-9
<sup>31</sup> P/ <sup>1</sup> H/ <sup>13</sup> C and DEPT NMR spectra of 2-Cyanoethoxy-seleno-thiophospholane, <b>9</b> .....	10-13
<sup>31</sup> P/ <sup>1</sup> H/ <sup>13</sup> C and DEPT NMR spectra of uridine-2',3'-O,O-phosphoroselenoate ( <i>Sp</i> , <i>exo</i> ) <b>10</b> .....	14-17
<sup>31</sup> P/ <sup>1</sup> H/ <sup>13</sup> C and DEPT NMR spectra of uridine-2',3'-O,O-phosphorothioate ( <i>Sp</i> , <i>exo</i> ), <b>11</b> .....	18-21
<sup>31</sup> P/ <sup>1</sup> H/ <sup>13</sup> C and DEPT NMR spectra of adenine-2',3'-O,O-phosphorothioate ( <i>Sp</i> , <i>exo</i> ), <b>12</b> .....	21-25
<sup>31</sup> P/ <sup>1</sup> H/ <sup>13</sup> C and DEPT NMR spectra of thymine-2',3'-O,O-phosphorothioate ( <i>Sp</i> , <i>exo</i> ), <b>13</b> .....	26-29
<sup>31</sup> P/ <sup>1</sup> H/ <sup>13</sup> C and DEPT NMR spectra of cytosine-2',3'-O,O-phosphorothioate ( <i>Sp</i> , <i>exo</i> ), <b>14</b> .....	30-33
<sup>31</sup> P/ <sup>1</sup> H/ <sup>13</sup> C and DEPT NMR spectra of guanine- 2',3'-O,O-phosphorothioate ( <i>Sp</i> , <i>exo</i> ), <b>15</b> .....	34-36
Fig.1 Nosey spectrum of solutions containing 1M of uridine and 1M of DBU-----	37
Schemes S1 and S2 -----	38

## Experimental

### General

All commercial reagents were used without further purification, unless otherwise noted. All air- and moisture sensitive reactions were conducted in flame-dried, nitrogen-flushed, two-neck flasks sealed with rubber septa, and the reagents were introduced with a syringe. Progress of the reactions was monitored by TLC using precoated Merck silica gel plates (60F-253). Reactants and products were visualized using UV light. Compounds were characterized by NMR using a Bruker DMX-600 spectrometer.  $^1\text{H}$  NMR spectra were recorded at 600 MHz. Nucleotides were also characterized by  $^{31}\text{P}$  NMR in  $\text{D}_2\text{O}$  at 161.96 MHz. High-resolution mass spectra were recorded on an AutoSpec-ESI mass spectrometer. Nucleotides were analyzed using electron spray ionization (ESI) on a Q-TOF micro-instrument (Waters). Primary purification of the nucleotides was achieved on a combi flash RF+ Teledyne ISCO system using a column of Sephadex DEAE-A25, swollen in 1 M  $\text{NaHCO}_3$  at 4 °C for 24 h. The resin was washed with deionized water before use. LC separation was monitored by UV detection at 260 nm and 220 nm. Final purification of the nucleotides was achieved on an HPLC (Merck-Hitachi) system using a semipreparative reversed-phase column [Gemini 5u C-18 110A, 250 mm  $\times$  10 mm, 5  $\mu\text{m}$  (Phenomenex, Torrance, CA)]. The details of the solvent system gradients used for the separation of each product are provided below. Specific rotation was measured by a Jasco P-2000 polarimeter using an aperture of 8 mm with a cuvette of 0.5 dm, in  $\text{H}_2\text{O}$  solution at 22 °C, with Na as a light source at 589 nm.

### 2-Cyanoethoxy-dithiophospholane, **8**, and 2-cyanoethoxy-seleno-thiophospholane, **9**

Hydroxypropionitrile was added dropwise into 2-chloro-dithiophospholane, **6**, in pyridine. The reaction mixture was stirred at room temperature for 30 min. Then excess of  $\text{S}_8$  or  $\text{Se}_0$  was added and the reaction mixture was stirred for 2 h. The solvent was removed under vacuo. Toluene (15 mL) was added to the residue. The solution was stirred and then the solvent was evaporated. Finally, acetonitrile (20 mL) was added to the residue and the excess of sulfur/selenium was filtered off. The crude product was purified by silica gel column chromatography using chloroform as an eluent.

### 2-Cyanoethoxy-thio-dithiophospholane, **8**

Starting from 3-hydroxypropionitrile (5.2 g, 5 mL, 0.07 mol) and 2-chloro-di-thiophospholane (10.9 g, 6.86 mL, 0.07 mol), product **8** was obtained as a colorless oil (10.5 g, 67% yield, 0.04 mol).  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ ): 123 (s) ppm.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$ : 4.3 (m, 2H), 3.6 (s, 4H), 2.8 (m, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100.61 MHz)  $\delta$ : 116, 61, 41, 19 ppm. HRMS ESI (negative) m/z: calculated: 223.94329, found: 223.94358.

### 2-Cyanoethoxy-seleno-dithiophospholane, **9**

Starting from 3-hydroxypropionitrile (5.2 g, 5 mL, 0.07 mol) and 2-chloro-di-thiophospholane (10.9 g, 6.86 mL, 0.07 mol), product **9** was obtained in 72% yield (13.8 g, 0.05 mol) as a colorless oil:  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ ): 106 (s) ppm.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$ : 4.2 (m, 2H), 3.7 (s, 4H), 2.8 (m, 2H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100.61 MHz)  $\delta$ : 116, 62, 43, 19 ppm. HRMS ESI (negative) m/z: calculated: 271.8876, found: 271.8875.

### 2-Cyanoethoxy-thio-1,3,2-dithiaphosphinane, **10**

Starting from 3-hydroxypropionitrile (5.2 g, 5 mL, 0.07 mol) and 2-chloro-1,3,2-dithiaphosphorinane, (12.04 g, 0.07 mol), and following the above general procedure, product **10** was obtained in 90 % yield (14.9 g, 0.06 mol) as a white solid. <sup>31</sup>P NMR (CDCl<sub>3</sub>): 85 (s) ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ: 4.2 (m, 2H), 3.3 (m, 4H), 3.1(t, 2H), 2.4 (d, 1H), 1.9 (d, 1H) ppm. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.61 MHz) δ: 117, 57, 35, 25, 19 ppm. HRMS ESI (negative) m/z: calculated: 238.9876, found: 238.9869.

### Nucleosides-2',3'-O,O-phosphorothioate (*Sp*, *exo*), **1A** and **12-15**. General procedure

2-Cyanoethoxy-dithiophospholane, **8** (2.05 mmol), dry triethylamine (0.2 mL), and nucleoside (2.05 mmol) were suspended in dry acetonitrile (15 mL). Then, DBU (0.5 mL, 3 mmol) was added, the reaction was stirred for 1 min. Finally, the reaction mixture was cooled in an ice bath and 0.5 M TEAB (10 mL) was added dropwise and the reaction mixture was stirred for 20 min. The reaction solution was evaporated. The aqueous phase was freeze-dried and separated by ion-exchange liquid chromatography on a Sephadex® DEAE A-25 column with a linear gradient of 0-0.1 M NH<sub>4</sub>HCO<sub>3</sub> buffer (pH 7.5). The product was further purified on RP18 (eluent: 0.5 M TEAA buffer (pH 7) and 10% CH<sub>3</sub>CN).

### Uridine-2',3'-O,O-phosphorothioate (*Sp*, *exo*), **1A**

2-Cyanoethoxy-dithiophospholane, **8** (460 mg, 2.05 mmol), dry triethylamine (0.2 mL), and uridine (500 mg, 2.05 mmol) were suspended in dry acetonitrile (15 mL). DBU (0.5 mL, 3 mmol) was then added. The product was obtained as the triethylammonium salt at 68 % overall yield (430 mg, 1.32 mmol). <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ: 7.6 (d, 1H, J 10.8 Hz), 5.86 (s, 1H), 5.78 (d, 1H, J 10.8 Hz), 5.18 (t, 1H, J 6.9 Hz), 4.9 (q, 1H, J 4.6 Hz), 4.28 (s, 1H), 3.7 (m, 2H) ppm. <sup>31</sup>P NMR (D<sub>2</sub>O, 161.96 MHz) δ: 77.26 (s) ppm. <sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz) δ: 168, 152, 146, 104, 94, 87, 84, 80, 63 ppm. HRMS ESI (negative) m/z: calculated: 323.9813, found: 323.9824.  $[\alpha]_{589}^{22}$  (L 0.05 dm) -16.68 cm<sup>2</sup>g<sup>-1</sup>

### Uridine-2',3'-O,O-phosphoroselenoate (*Sp*, *exo*), **11**

2-Cyanoethoxy-seleno-thiophospholane, **9** (480 mg, 2.05 mmol), dry triethylamine (0.2 mL), and uridine (500 mg, 2.05 mmol) were suspended in dry acetonitrile (15 mL). DBU (0.5 mL, 3 mmol) was then added to the reaction solution. The reaction mixture was stirred for 1 min. Finally, the reaction mixture was cooled in an ice bath and 0.5 M TEAB (10 mL) was added dropwise and the reaction mixture was stirred for 20 min. The reaction solution was evaporated. The residue was freeze dried and separated by liquid chromatography on a Sephadex® DEAE A-25 column with a linear gradient of 0- 0.1 M NH<sub>4</sub>HCO<sub>3</sub> buffer (pH 7.5), followed by separation on RP18 (eluent: 0.5 M TEAA buffer (pH 7) and 10% acetonitrile). The product was obtained as the triethylammonium salt at 61 % overall yield (459 mg, 1.24 mmol). <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ: 7.6 (d, 1H, J 10.8 Hz), 5.8 (s, 1H), 5.78 (d, 1H, J 10.8Hz), 5.2 (t, 1H, J 6.3 Hz), 4.9 (q, 1H, J 4.1 Hz), 4.3 (s, 1H), 3.8 (m, 2H) ppm. <sup>31</sup>P NMR (D<sub>2</sub>O, 161.96 MHz) δ: 66.9 (s) ppm. <sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz) δ: 167, 152, 145, 103, 94, 86, 83, 79, 62 ppm. HRMS ESI (negative) m/z: calculated: 368.9352, found: 368.9391,  $[\alpha]_{589}^{22}$  (L 0.05 dm) -51.41 cm<sup>2</sup>g<sup>-1</sup>

### Adenosine-2',3'-O,O-phosphorothioate (*Sp*, *exo*), **12**

2-Cyanoethoxy-dithiophospholane, **8** (460 mg, 2.05 mmol), dry triethylamine (0.2 mL), and adenosine (0.54 g, 2.05 mmol) were suspended in dry acetonitrile (15 mL). DBU (0.5 mL, 3 mmol) was then added. The product was obtained as the triethylammonium salt at 62 % overall yield (438 mg, 1.26 mmol). <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ: 8.34 (s, 1H), 8.26 (s, 1H), 6.34 (s, 1H), 5.54 (t, 1H), 5.24 (t, 1H), 4.5 (q, 2H), 3.9 (q, 2H) ppm. <sup>31</sup>P NMR (D<sub>2</sub>O, 161.96 MHz) δ: 77.34 (s) ppm. <sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz) δ: 157, 154, 149, 142, 120, 90, 86, 82, 80, 62 ppm. HRMS ESI (negative) m/z: calculated: 345.0296, found: 345.0290.  $[\alpha]_{589}^{22}$  (L 0.05 dm) -38.8 cm<sup>2</sup>g<sup>-1</sup>

#### **Thymidine-2',3'-O,O-phosphorothioate (Sp, exo), 13**

2-Cyanoethoxy-dithiophospholane, **8** (460 mg, 2.05 mmol), dry triethylamine (0.2 mL), and thymidine (520mg, 2.05 mmol) were suspended in dry acetonitrile (15 mL). DBU (0.5 mL, 3 mmol) was then added. The product was obtained as the triethylammonium salt at 68 % overall yield (468 mg, 1.39 mmol). <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ: 7.32 (s, 1H), 5.82 (s, 1H), 5.1 (t, 1H), 4.8 (q, 1H), 4.18 (s, 1H), 3.7 (m, 2H), 1.7 (s, 3H) ppm. <sup>31</sup>P NMR (D<sub>2</sub>O, 161.96 MHz) δ: 77.23 (s) ppm. <sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz) δ: 182, 175, 158, 140, 113, 93, 86, 83, 82, 79, 62, 13 ppm. HRMS ESI (negative) m/z: calculated: 336.0181, found: 336.0179.  $[\alpha]_{589}^{22}$  (L 0.05 dm) -9.132 cm<sup>2</sup>g<sup>-1</sup>


#### **Cytosine-2',3'-O,O-phosphorothioate (Sp, exo), 14**

2-Cyanoethoxy-dithiophospholane, **8** (460 mg, 2.05 mmol), dry triethylamine (0.2 mL), and cytidine (490 mg, 2.05 mmol) were suspended in dry acetonitrile (15 mL). DBU (0.5 mL, 3 mmol) was then added. The product was obtained as the triethylammonium salt at 50 % overall yield (329 mg, 1.02 mmol). <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ: 7.61 (s, 1H), 5.95 (s, 1H), 5.84 (s, 1H), 5.17 (t, 1H), 4.97 (q, 1H), 4.38 (s, 1H), 3.7 (m, 2H) ppm. <sup>31</sup>P NMR (D<sub>2</sub>O, 161.96 MHz) δ: 77.9 (s) ppm. <sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz) δ: 168, 158, 145, 97, 95, 86, 83, 80, 62, 42 ppm. HRMS ESI (negative) m/z: calculated: 321.0184, found: 321.0193.  $[\alpha]_{589}^{22}$  (L 0.05 dm) -45.83 cm<sup>2</sup>g<sup>-1</sup>


#### **Guanosine-2',3'-O,O-phosphorothioate (Sp, exo), 15**

2-Cyanoethoxy-dithiophospholane, **8** (460 mg, 2.05 mmol), dry triethylamine (0.2 mL), and guanosine (580 mg, 2.05 mmol) were suspended in dry acetonitrile (15 mL). DBU (0.5 mL, 3 mmol) was then added. The product was obtained as the triethylammonium salt at 20 % overall yield (148 mg, 4.09 mmol). <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ: 8.48 (s, 1H), 6.07 (s, 1H), 5.54 (s, 1H), 5.22 (t, 1H), 4.55 (q, 1H), 4.96 (s, 1H) ppm. <sup>31</sup>P NMR (D<sub>2</sub>O, 161.96 MHz) δ: 77.9 (s) ppm. <sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz) δ: 168, 158, 145, 97, 95, 86, 83, 80, 62, 42 ppm. HRMS ESI (negative) m/z: calculated: 361.0245, found: 361.0240.  $[\alpha]_{589}^{22}$  (L 0.05 dm) -29.8 cm<sup>2</sup>g<sup>-1</sup>


**$^{31}\text{P}/^1\text{H}/^{13}\text{C}$  and DEPT NMR spectra of 2-cyanoethoxy-dithiophospholane, 8**




$^{31}\text{P}$  NMR ( $\text{CDCl}_3$ , 161.96 MHz)



$^{31}\text{P}$  NMR ( $\text{CDCl}_3$ , 161.96 MHz)




$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)



<sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.61 MHz).






61.951  
61.875  
41.652  
19.639  
19.550




<sup>13</sup>C NMR (CDCl<sub>3</sub>, 100.61 MHz).


$^{31}\text{P}/^1\text{H}/^{13}\text{C}$  and DEPT NMR spectra of 2-Cyanoethoxy-seleno-thiophospholane, 9




$^{31}\text{P}$  NMR (CDCl<sub>3</sub>, 161.96 MHz)




$^{31}\text{P}$  NMR ( $\text{CDCl}_3$ , 161.96 MHz)



$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)




$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100.61 MHz).



$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100.61 MHz).

$^{31}\text{P}/^1\text{H}/^{13}\text{C}$  and DEPT NMR spectra of Uridine-2',3'-O,O-phosphoroselenoate (Sp, exo) **11**.



$^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ , 161.96 MHz).





```

Current Data Parameters
NAME      U2
EXPNO    1
PROCNO    1

F2 - Acquisition Parameters
Date_     20181015
Time     14.41
INSTRUM   spect
PROBHD    5 mm QNP 1H/1
PULPROG   zgpg30
TD        65536
SOLVENT   CDCl3
NS        1811
DS        0
SWH       40000.000 Hz
FIDRES    0.61335 Hz
AQ        0.8192500 sec
RG        6192
DSW       12.500 usec
DE        14.25 usec
TE        300.2 K
D1        0.50000000 sec
d11       0.03000000 sec
TD0       1



===== CHANNEL f1 =====
NUC1      13C
P1        5.00 usec
PL1       -2.00 dB
SFO1      101.6250013 MHz

===== CHANNEL f2 =====
C1P1P2    waltz16
NUC2      1H
PCPD2     100.00 usec
PL2       0.00 dB
PL12      19.40 dB
SFO2      500.1364000 MHz


F2 - Processing parameters
SI        65536
SF        101.6250000 MHz
WDW       EM
SSB       0
LB        2.00 Hz
GB        0
PC        1.00

```

167.79  
 152.62  
 145.32  
 103.58  
 94.116  
 94.082  
 86.879  
 83.463  
 79.816  
 62.411




<sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz).




<sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz).


$^{31}\text{P}/^1\text{H}/^{13}\text{C}$  and DEPT NMR spectra of Uridine-2',3'-O-phosphorothioate (*Sp*, *exo*), 10




$^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ , 161.96 MHz)



<sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz).




$^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ , 100.61 MHz).




<sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz).

$^{31}\text{P}/^1\text{H}/^{13}\text{C}$  and DEPT NMR spectra of adenine-2',3'-O,O-phosphorothioate (*Sp*, *exo*), 12.





$^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ , 161.96 MHz)




<sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz)






$^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ , 100.61 MHz).




$^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ , 100.61 MHz).


$^{31}\text{P}/^1\text{H}/^{13}\text{C}$  and DEPT NMR spectra of thymine-2',3'-O,O-phosphorothioate (*Sp*, *exo*), **13**.




$^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ , 161.96 MHz)



<sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz)




$^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ , 100.61 MHz).




<sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz).

$^{31}\text{P}/^1\text{H}/^{13}\text{C}$  and DEPT NMR spectra of cytosine-2',3'-O,O-phosphorothioate (*Sp*, *exo*), **14**.






$^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ , 161.96 MHz)




<sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz)






<sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz).




<sup>13</sup>C NMR (D<sub>2</sub>O, 100.61 MHz).

$^{31}\text{P}/^1\text{H}/^{13}\text{C}$  and DEPT NMR spectra of guanine-2',3'-O,O-phosphorothioate (*Sp*, *exo*), **15**.



$^{31}\text{P}$  NMR ( $\text{D}_2\text{O}$ , 161.96 MHz)



$^1\text{H}$  NMR ( $\text{D}_2\text{O}$ , 400 MHz)

Nosey spectrum of solutions containing 1M of uridine and 1M of DBU






Fig1. All the NOE interactions observed are intramolecular, no NOE interactions are observed between uridine and DBU protons.  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ , 400 MHz),  $^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ , 100.61 MHz).



Scheme S1. Ramsay-Shaw's synthesis of epimeric uridine-2',3'-cyclic thio-phosphate, **1(A+B)**.



Scheme S2. Kraszewski's synthesis of epimeric uridine-2',3'-cyclic thio-phosphate, **1(A+B)**. All reported syntheses of nucleoside 2',3'-cyclic (thio or dithio)monophosphate have involved a 5'-OH protection/deprotection strategy.